TY - JOUR
T1 - Managing the Child with Persistent Sleep Apnea
AU - Bluher, Andrew E.
AU - Ishman, Stacey L.
AU - Baldassari, Cristina M.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Pediatric obstructive sleep apnea (OSA) affects 2% to 4% of American children, and is associated with metabolic, cardiovascular, and neurocognitive sequelae. The primary treatment for pediatric OSA is adenotonsillectomy. Children with obesity, craniofacial syndromes, and severe baseline OSA are at risk for persistent disease. Evaluation of persistent OSA should focus on identifying the causes of upper airway obstruction. Interventions should be tailored to address the patient's symptomatology, sites of obstruction, and preference for surgical versus medical management. Further research is needed to identify management protocols that result in improved outcomes for children with persistent OSA.
AB - Pediatric obstructive sleep apnea (OSA) affects 2% to 4% of American children, and is associated with metabolic, cardiovascular, and neurocognitive sequelae. The primary treatment for pediatric OSA is adenotonsillectomy. Children with obesity, craniofacial syndromes, and severe baseline OSA are at risk for persistent disease. Evaluation of persistent OSA should focus on identifying the causes of upper airway obstruction. Interventions should be tailored to address the patient's symptomatology, sites of obstruction, and preference for surgical versus medical management. Further research is needed to identify management protocols that result in improved outcomes for children with persistent OSA.
KW - DISE
KW - Pediatric obstructive sleep apnea
KW - Persistent OSA
KW - Tongue base obstruction
UR - https://www.scopus.com/pages/publications/85068522638
U2 - 10.1016/j.otc.2019.06.004
DO - 10.1016/j.otc.2019.06.004
M3 - Review article
C2 - 31301824
AN - SCOPUS:85068522638
SN - 0030-6665
VL - 52
SP - 891
EP - 901
JO - Otolaryngologic Clinics of North America
JF - Otolaryngologic Clinics of North America
IS - 5
ER -